Clinical Trial

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

Study acronym: NEPHRON
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 9, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-29; most recent amendment 2026-03-05.
Trial Details
NCT Number NCT07223502
Lead Sponsor Sarfez Pharmaceuticals, Inc.
Conditions Hypertension (HTN)
Enrollment 30 participants
Start Date 2025-12-01
Primary Completion 2026-07 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-09